Manufacturing consultancy up 150% as life sciences prepare for a digital future
Increasing appetite for digitised manufacturing and using data to improve GMP manufacturing.
Zenith Technologies has seen a 150% rise in demand for its consultancy arm services. The company's consultancy has seen an increasing appetite for digitised manufacturing and using data to improve GMP manufacturing over the past 12 months.
The growth of the service in 2018 was driven by a need to aid customers in collecting, contextualising and finding insights in their stored data. These insights can then be used to make informed decisions on production processes and the supply chain.
Jaqueline Hora, Global Digital and Data Analytics Lead at Zenith Technologies said: “The life science industry has seen a remarkable trend towards innovation utilising data and technology effectively. Digital strategies, as well as manufacturing execution systems (MES) and automation, are in great demand as a result.
“For customers implementing these digital strategies, project decision support as well as process, technology and project execution knowledge, are essential to ensure success.
“Our Consultancy team supports customers that are considering new technology projects and assists in developing strategies, governance and standards to provide a framework for success.
“Whether it be justifying ROI, validating a customer’s strategy, process and methodology implementation expertise or help with technology selection, Zenith has been there to support its customer base.
“Zenith’s intimate understanding of manufacturing systems, extensive process knowledge and significant experience serving the life science sector has ensured that our customers have the insight needed to make the best decision.”
The increase is in part a direct result of the emergence of Industry 4.0 with data integrity, data analytics, the internet of things, and cloud strategies becoming a reality throughout the life science industry.
The team’s growth is projected to continue into 2019 as the life science industry increases its focus on digitisation and using data to improve GMP manufacturing practices.
In a recent survey of the industry, Zenith found nearly 60% of participants believe that Industry 4.0 will drive the most change in life science over the next 5 years, with 75% of those aiming to invest in people to take advantage of emerging technologies.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance